1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zenotech Laboratories Limited

Zenotech Laboratories Limited

BBSE:ZENOTECH
40.31
INR
+0.81
(+2.05%)
-0.41EPS
2.69BMarket Cap
Zenotech Laboratories Limited
BSE:ZENOTECH
(Bombay Stock Exchange)

Recent

price

40.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
1.93
0.6
0.84
0.76
1.12
0.57
0.62
2.1
2.13
4.25
3.17
5.32
6.28
6.02
6.39
6.48
6.6
Revenue per Share
-10.43
-2.83
-7.04
-6.3
-8.38
-5.28
-5.48
-2.24
-0.51
1.77
-0.2
3.63
1.9
1.36
0.92
-0.18
-0.41
Basic EPS, GAAP
0.02
-0.5
-2.9
-6.97
-2.14
-1.32
0.26
-3.79
-5.26
-1.7
0.14
2.58
2.36
1.24
0.92
0.31
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
17.06
14.23
7.2
0.9
-7.43
-12.7
-18.17
6.88
6.37
8.13
7.93
11.57
13.48
14.84
15.75
15.59
- -
Book Value per Share
17.06
14.23
7.2
0.9
-7.43
-12.7
-18.17
6.88
6.37
8.13
7.93
11.57
13.48
14.84
15.75
15.59
- -
Tangible Book Value per Share
36
36
36
36
36
36
36
53
61
61
61
61
61
61
61
61
61
Basic Weighted Avg Shares
70
22
30
28
41
21
23
111
130
259
194
325
384
368
390
396
405
Sales/Revenue/Turnover
-200.32
-380.78
-771.21
-678.01
-587.74
-556.04
-632.28
-104.99
-57.7
15.63
-16.25
19.75
24.67
16.6
8.16
-4.8
0.86
Operating Margin (%)
51
35
35
36
41
40
39
39
42
48
65
70
72
71
70
71
72
Depreciation Expense
-378
-103
-255
-229
-304
-191
-199
-119
-31
108
-12
222
116
83
56
-11
-25
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
20.11
25.51
47.5
125.59
208.9
Effective Tax Rate (%)
-540.44
-469.82
-838.41
-829.39
-746.05
-929.09
-881.41
-106.34
-24
41.55
-6.27
68.25
30.21
22.57
14.4
-2.71
-6.21
Profit Margin (%)
-65
-139
-357
-556
-820
-962
-1,146
-80
-262
-297
-76
-82
-3
126
234
290
- -
Working Capital
1
1
2
1
- -
- -
- -
- -
- -
- -
207
60
- -
- -
- -
- -
- -
LT Debt
619
516
261
32
-270
-461
-659
420
389
496
484
706
823
905
961
951
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.35
- -
- -
9.55
5.22
2.84
0.56
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.32
- -
- -
14.69
9.6
6.01
-1.12
- -
Return on Capital (%)
-46.82
-18.08
-65.67
-155.73
- -
- -
- -
- -
-7.73
24.35
-2.48
37.26
15.15
9.6
6.01
-1.12
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
2,819
2,093
2,685

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
410
- -
Cash, Cash Equivalents & STI
- -
304
- -
Accounts Receivable, Net
- -
88
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
121
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.54%
15.51%
-1.05%
Free Cash Flow
-84.78%
329.65%
-66.53%
Net Income, GAAP
-281.87%
-430.52%
-119.1%
Sales/Revenue/Turnover
58.36%
17.82%
1.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
89
87
102
111
390
2026
86
102
118
89
396
2027
96
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.21
0.22
0.28
0.2
0.92
2026
0.16
-0.14
0.32
-0.52
-0.18
2027
-0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zenotech Laboratories Limited manufactures and markets pharmaceutical specialty generic injectables and biotechnology products, primarily in oncology, anesthesiology, and related therapeutic areas; its core offerings include oncology injectables, general injectables, parenteral depot formulations, ophthalmic products, oncology oral formulations, granulocyte-colony stimulating factors, granulocyte-macrophage colony-stimulating factors, and contract manufacturing services for these categories. The company, founded in 1989 and headquartered in Hyderabad, Telangana, India, operates as a subsidiary of Sun Pharmaceutical Industries Limited, which holds a majority stake following acquisitions including an increase to 57.56% in 2017 via rights issue and a further 11.28% purchase from Daiichi Sankyo in 2022, elevating ownership to 68.84%. Zenotech focuses on the Indian market with niche biotech capabilities, leasing facilities and equipment while reporting recent financial performance with sales growth to Rs 38.98 crore for the year ended March 2025 amid fluctuating quarterly profits.